BIH Lecture | Thomas Kaiser "Transparency Matters: A Tale of 1000 and 1 Drug Assessments"

Wie schafft das AMNOG-Verfahren größere Transparenz bei der Arzneimittelbewertung? Erfahren Sie, warum die vollständige Offenlegung von Herstellerdaten entscheidend ist und wie die kommende europäische Nutzenbewertung (EU-HTA) die Zukunft der Arzneimittelbewertung prägen wird.
Language
This page is only available in English.
The online talk is part of the “Frontiers in Translational Medicine - Scientific and Structural Challenges” on key questions of translation in medicine.
BIH Lecture
"Transparency Matters: A Tale of 1000 and 1 Drug Assessments"
In 2011, Germany implemented a systematic drug assessment process called AMNOG. Transparency is key to AMNOG: All data must be submitted by the manufacturer and the assessment is published in full. This talk will illustrate why this matters and provide a perspective on the forthcoming European benefit assessment (EU-HTA).
About the Speaker
Thomas Kaiser
Director of the Institute for Quality and Efficiency in Health Care (IQWiG).
Physician and System Developer. Co-founder of the German Institute for Evidence-based Medicine (DIeM), Cologne, in 2002. From the founding of the Institute for Quality and Efficiency in Health Care (IQWiG) in 2004 until 2023: Head of the Drug Assessment Department. Director of IQWiG since 1 April 2023. Recipient of the Bill Silverman Prize of the Cochrane Collaboration (together with 3 other IQWiG staff members) in 2008. Recipient of the David Sackett Prize of the German Network for Evidence-based Medicine (DNebM) in 2011 (prize awarded to IQWiG‘s Drug Assessment Department).
Info
When
December 4, 2026
12:00 - 1:00 pm
Where
Online via Zoom
>> The login link will be provided shortly before the event.
Registration
Please register here.
